Utah is currently home to 1224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Home-Based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation
NCT06291922
Recruiting
The goal of this clinical trial is to evaluate the effects of a home-based exercise program using mobile technology on physical activity and capacity, frailty and muscle mass, and quality of life in patients with a newly implanted HeartMate 3 left ventricular assist device (HM3 LVAD). Researchers will compare the effects of an exercise intervention vs. usual care on physical activity and capacity, frailty and muscle mass, and quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Heart Failure
Register for Updates
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
NCT06239480
Recruiting
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/26/2025
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Microcystic Lymphatic Malformation
Register for Updates
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
NCT05859334
Recruiting
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, Recurrent Glioma
Register for Updates
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Research Site, Salt Lake City, Utah
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177
Recruiting
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Colorectal Cancer
Register for Updates
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
NCT04963153
Recruiting
This phase Ib trial evaluates the best dose, potential benefits, and/or side effects of erdafitinib in combination with enfortumab vedotin in treating patients with bladder cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and possesses genetic alterations in FGFR2/3 genes. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage IV Urethral Cancer AJCC v8, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8
Register for Updates
Immune Cells During Disuse and Recovery
NCT04416191
Recruiting
This is an interventional study enrolling healthy individuals aged 18-35 and 60-85 to understand the recovery of muscle health following a period of inactivity. The enrollment goal is 45 participants. The study will occur over the course of 1-2 months where participants will undergo testing before and after a 2-week limb immobilization period.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/26/2025
Locations: The University of Utah, Salt Lake City, Utah
Conditions: Muscle Disuse
Register for Updates
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883
Recruiting
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/26/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Register for Updates
A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants
NCT06727136
Recruiting
The main purpose of the study is to characterize the systemic pharmacokinetic (PK) parameters (plasma, whole blood) of tebipenem (TBP) pharmacologically active moiety of tebipenem-pivoxil-hydrobromide (TBP-PI-HBr) and its urinary excretion at different dose levels in healthy participants. The study also aims to assess the plasma and urine PK parameters of SPR1349, a major metabolite of TBP.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/25/2025
Locations: Medical Facility, Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Participants
Register for Updates
Trial to Evaluate Safety and Effectiveness of Mechanical Circulatory Support in Patients with Advancing Heart Failure
NCT06526195
Recruiting
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Register for Updates
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
NCT06502366
Recruiting
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Research Site, West Jordan, Utah
Conditions: Asthma
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Compared with Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178
Recruiting
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Site 4, Salt Lake City, Utah
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates